Naslov
Eradication of Helicobacter pylori with Four One-week Triple Therapy Regimens Containing Azithromycin

Autori
Katičić, Miroslava ; Tićak, Mirjana ; Prskalo, Marija ; Papa, Branko ; Dominis, Mara ; Presečki, Vladimir ; Pavić-Sladoljev, Dubravka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract book, ICMAS 5 / ICMAS - Sevilla : ICMAS, 2000

Skup
ICMAS 5

Mjesto i datum
Sevilla, Španjolska, 26.01.2000. - 28.01.2000

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Helicobacter pylori; therapy; eradication
(Helicobacter pylori; therapy; erdaication)

Sažetak
The aim of the clinical study was to compare the efficacy and tolerability of four one-week triple therapy regimens containing azithromycin. Patients and Methods: Inclusion criteria: patients of both sexes, aged 18 years; patients with history of peptic ulcer or patients presenting with dyspepsia, with or without active ulceration (proven by endoscopy); patients with Helicobacter pylori positive urease test. Exclusion criteria: pregnancy or lactation; hypersensitivity to penicillins, nitromidazoles,macrolides or PPIS; NSAID therapy, corticosteroids; evidence of chronic renal or liver diseases, gastric surgery or vagotomy; chronic alcohol abuse. Helicobacter pylori status was assessed by urease test, histology, microbiology and 13C urea breath test 13C-UBT and the begining of the study and 4 weeks after completition of therapy. Clinical status (ulcer healing, clinical improvement) was assessed 4 weeks after completion of therapy. Patients presenting with peptic ulcer or non-ulcer syspepsia were randomly treated with 4 different triple therapies containing azithromycin: omeprazole, amoxicillin, azithromycin (OAAz), omeparzole, amoxicillin and azithromycin (OMAz), pantoprazole, amoxicillin and azithromycin (PMAz). Duration of therapy and number of patients are shown in table 1. Results: A totoal of 156 Hp positive patients with duodenal ulcer (DU), gastric ulcer (GU) and non-ulcer dyspepsia (NUD) were included into study. Distribution of patients according to their diagnosis with the terapeutic groups is shown in table 2. Helicobacter pylori eradication (Helicobacter pylori negative by urease test, histology, microbiology and 13C-UBT 4 weeks after completion of therapy) was achieved in 30/38 (79 per cent) patients treated with OAAz, 30/36 (79 per cent) treated with OMAz, 31/42 (74 per cent) treated with PAAz, and in 33/40 (83 per cent) patients treated with PMAz. Overall clinical cure (healing/improvement) was achieved in 36/38 (95 per cent) patients treated with OAAz, 34/36 (94 per cent) treated with OMAz, 38/42 (90 per cent) treated with PAAz, and in 39/40 (98 per cent) patients treated with PMAz. Conclusion: There were no statistically significant difference in the healing rate and clinical improvement between the four therapy regimens comtaining azithromycin. Eradication rates were higher in therapeutic groups containng metronidazole, with no significant differences between all 4 therapy regimens (p gt then 0.05)

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA